Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (opent nieuw venster)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Bron‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Geïndexeerd‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (opent nieuw venster)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (opent nieuw venster)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Bron‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Geïndexeerd‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (opent nieuw venster)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (opent nieuw venster)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Bron‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Geïndexeerd‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (opent nieuw venster)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (opent nieuw venster)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Bron‎: Blood 2003;102(4):1529-30.

Geïndexeerd‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (opent nieuw venster)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (opent nieuw venster)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Bron‎: Transfusion 2007;47(10):1830-6.

Geïndexeerd‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (opent nieuw venster)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (opent nieuw venster)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Bron‎: Iran J Blood Cancer 2009;1(4):147-50.

Geïndexeerd‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (opent nieuw venster)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (opent nieuw venster)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Bron‎: Int J Hematol 2012;95(1):51-6.

Geïndexeerd‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (opent nieuw venster)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (opent nieuw venster)

Perrine SP.

Bron‎: Pediatr Ann 2008;37(5):339-46.

Geïndexeerd‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (opent nieuw venster)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (opent nieuw venster)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Bron‎: Sci Rep. 2022;12(1):2752.

Geïndexeerd‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (opent nieuw venster)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (opent nieuw venster)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Bron‎: Haematologica 2004;89(10):1172-8.

Geïndexeerd‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (opent nieuw venster)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (opent nieuw venster)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Bron‎: Arch Iran Med 2009;12(3):295-7.

Geïndexeerd‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (opent nieuw venster)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (opent nieuw venster)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Bron‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Geïndexeerd‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (opent nieuw venster)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (opent nieuw venster)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Bron‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Geïndexeerd‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (opent nieuw venster)

Fetal globin gene inducers: novel agents and new potential. (opent nieuw venster)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Bron‎: Ann N Y Acad Sci 2010;1202:158-64.

Geïndexeerd‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (opent nieuw venster)